natgillin/translations-raw huggingface dataset:
A compound of formula (I) or a physiologically acceptable solvate thereof for use in the treatment of patients according to claim 5, wherein the inflammatory and/or allergic condition is rhinitis. 
Spoj formule (I), ili njegov fiziološki prihvatljiv solvat, u skladu s patentnim zahtjevom 13, naznačen time što je namijenjen upotrebi u liječenju pacijenata s rinitisom.
A composition for use according to claim 8 or 9, wherein the disease or condition is asthma or chronic obstructive pulmonary disease (COPD). 
Pripravak za primjenu prema zahtjevu 8 ili 9, naznačen time, što je bolest 1li stanje astma ili kronična opstruktivna plućna bolest (COPD).
After stirring at room temperature for 45 minutes, water (234 ml) was added and the mixture extracted with ether (2 x 200 ml). 
Nakon miješanja na sobnoj temperaturi tijekom 45 minuta, doda se voda (234 ml) i smjesa se ekstrahira eterom (2 x 200 ml).
and is The compound as claimed in claim 1, wherein the compound is selected from the group consisting of: 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time da je spoj je izabran iz grupe koja se sastoji od:
The combination of claim 4, wherein the combination is for administration of 20 mg per day of the compound of formula (I) and less than 3 mg per day of haloperidol. 
Kombinacija prema zahtjevu 4, naznačena time da je kombinacija za davanje 20 mg dnevno spoja sa formulom (I) i manje od 3 mg dnevno haloperidola.
Composition comprising at least one human Tr1 cell population directed against a joint-associated antigen, provided said joint-associated antigen is not HSP, keratin, pyruvate deshydrogenase, topoisomerase I, cardiolipin or collagen type IV. 
Smjesa koja obuhvaća najmanje jednu populaciju ljudskih Tr1 stanica koje djeluju protiv kolagena tipa II za upotrebu u liječenju artritičnih stanja u potrebitih pacijenata.
A method of inhibiting or preventing platelet aggregation, which comprises the step of administering to a subject in need thereof a therapeutically effective amount of a compound as defined in claim 1 . 
Spoj kao što je definirano u bilo kojem od patentnih zahtjeva 4 do 7 za primjenu u liječenju tromboembolijskog poremećaja ili primarnoj ili sekundarnoj profilaksi tromboembolijskog poremećaja.
A composition comprising a compound or composition according to any one of claims 1-17 and an additional anti-inflammatory agent, wherein said additional anti-inflmmatory agent preferably is an a4B7 inhibitor, a steroid, a MMP-9 antibody, a S1P1 agonist, a TNF biologic, or any combination thereof. 
Sastav koji sadrži spoj ili sastav prema bilo kojem od zahtjeva 1-17 i dodato antiinflamatorno sredstvo, gdje je spomenuto dodatno anti-inflamatorno sredstvo poželjno a4B7 inhibitor, steroid, MMP9 antitijelo, S1P1 agonist, TNF biološko sredstvo, ili bilo koja njihova kombinacija.
2-amino-6-bromo-8-cyclopentyl-4-methylpyrido[2,3 -d]pyrimidin-7(8 H)-one; and optionally as a pharmaceutically acceptable salt or solvate thereof. 
2-amino-6-bromo-8-ciklopentil-4-metilpirido[2,3-d]pirimidin-7(8H)-on; i izborno kao njegova farmaceutski prihvatljiva sol ili solvat.
In one aspect the invention is directed to a method of preparing a fuel, comprising co-processing a feedstock in the presence of a catalyst, the fuel comprising a product of a fluidized catalytic cracker co-processing a feedstock, said feedstock comprising: i) 80-99.95 wt.% of a petroleum fraction feedstock; and ii) 0.05-7 wt.% of an unenriched renewable fuel oil feedstock, the unenriched renewable fuel oil being formed from mechanically grinding a cellulosic biomass followed by rapid thermal processing, exclusive of hydrodeoxygenation, hydrotreating, or catalytic processing. wherein the unenriched renewable fuel oil has a) in the range of between 35-80 wt.% carbon content on a moisture free basis; b) and in the range of between 20-50 wt.% oxygen content on a moisture-free basis; and c) a water content in the range of between 10-40 wt.%. 
HR P20190597 T1 PATENTNI ZAHTJEVI Postupak proizvodnje goriva, koji sadrži: ko-procesiranje sirovine u prisutnosti katalizatora, gorivo sadrži proizvod fluidiziranog katalitičkog krekera koji ko-procesira sirovinu, navedena sirovina sadrži: i) 80-99,95 wt. % sirovine frakcije petroleja; i 11)0,05-7 wt. % sirovine neobogaćenog obnovljivog ulja goriva, neobogaćeno obnovljivo ulje goriva nastaje mehaničkim mljevenjem celulozne biomase nakon čega slijedi brzo termalno procesiranje, isključivo od hidrodeoksigenacije, hidrotretiranja ili katalitičkog procesiranja, naznačen time što neobogaćeno obnovljivo ulje goriva ima a) u rasponu od između 35-80 wt. % sadržaja ugljika na bazi bez vlage; b) te u rasponu od između 20-50 wt. % sadržaja kisika na bazi bez vlage; te c) sadržaj vode u rasponu od između 10-40 wt. %.
In an embodiment of the invention, the free concentration of Mn2+ in the blood is less than 10 nM, 7 nM, 5 nM, 3 nM, 2 nM, 1 nM, 700 pM, 500 pM, 300 pM, 200 pM 100 pM, 70 pM, 50 pM, 30 pM, 20 pM or 10 pM as measured from blood serum. 
Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u krvi, a slobodna koncentracija Mn"* u krvi je manja od 10nM, 1 nM, 100 pM ili 10 pM, što je izmjereno u krvnom serumu.
The method of claim 1, wherein said compound is represented by the structure of formula VIII: 
VII 4. Spoj iz zahtjeva 1, okarakteriziran strukturnom formulom VIII:
separating the trans-(−)-A9-THC and the trans-(+)-A9-THC from the alcoholic-caustic phase; and 
(b) separaciju trans-(-)-A'-tetrahidrokanabinola od alkoholno-kaustične faze; i
A method for providing high microbiological quality cooling water to an industrial process, where the industrial process comprises an industrial plant, the method comprising: 
Uređaj obuhvaća sustav za izvođenje industrijskog postupka (9) i sustav za omogućavanje rashladne vode visoke mikrobiološke kvalitete za navedeni sustav za izvođenje industrijskog postupka, pri čemu sustav za izvođenje industrijskog postupka obuhvaća industrijsko postrojenje, uređaj obuhvaća:
The compound of claim 1 having the formula: or or a pharmaceutically acceptable tautomer, salt, or stereoisomer thereof. 
? HCENO DÅ NH O ili njegov farmaceutski prihvatljiv tautomer, sol ili stereoizomer.
The food processing apparatus (10) of claim 8, wherein the driven member further comprises a reinforced matrix (34b) at least partially surrounding the pole elements (34a). 
Uređaj za obradu hrane (10) iz zahtjeva 8, pri čemu član koji se pokreće nadalje sadrži pojačanu matricu (34b) koja barem djelomice okružuje elemente šipke (34a).
The lens is connected to a camera so that the surgeon can view the inside of the body on a screen. 
Ova leća se spaja na kameru tako da kirurg može vidjeti unutrašnjost tijela na ekranu.
Accordingly, in use of the invert arm assembly, the ball spline shaft assembly and its motor 44, and the ball screw assembly and its motor 50, are assembled into the housing 20 and the housing 20 is closed and sealed. 
U skladu s tim, prilikom korištenja sklopa invertirajuće ruke, sklop kuglasto-klinaste osovine i njen motor (44), te sklop kuglastog vijka s kuglastim zaticima i njegov motor (50), su uklopljeni u kućište (20), koje se zatvara i zabrtvljuje.
an inhalation device containing an agent of the invention in inhalable form. 
(d) napravu za inhalaciju koja sadrži sredstvo izuma u obliku koji se može inhalirati.
The resulting crude is purified by chromatography on silica eluting with ethyl acetate/iso-hexane (20-100% ethyl acetate) to yield the titled compound as a green oil. 
Dobiveni sirov proizvod sc očisti kromatografijom na stupcu silika gela ispirući s etil acetat/izo-heksanom (20-100% etil acetat), čime se dobije naslovni spoj kao zeleno ulje.
a recombinant antigen receptor, which binds an antigen; and a vector encoding a co-stimulatory ligand, which co-stimulatory ligand is CD80 or 4-1BBL. 
T-stanica koja sadrži: rekombinantni receptor antigena, koji veže antigen; i vektor koji kodira ko-stimulacijski ligand, navedeni ko-stimulacijski ligand je CD80 ili 4-IBBL.
The reaction mixture was then stirred at room temperature for two hours. 
Reakcijska smjesa se zatim miješa na sobnoj temperaturi tijekom dva sata.
After 30 minutes at room temperature, the reaction was quenched with water and extracted with ethyl acetate (2×). 
Nakon miješanja na sobnoj temperaturi tijekom 30 minuta, reakcija se prekine vodom i ekstrahira s etil acetatom (2x).
A therapeutically effective amount of a composition comprising laminin-1 and a chelating agent for use in enhancing muscle regeneration or repair in a subject, or for use in preventing or reducing muscular damage in a subject, wherein the composition is to be administered systemically and wherein said muscle regeneration is after damage, injury or disease. 
Neka terapeutski djelotvorna količina laminina-1 za pospješivanje regeneracije mišića ili zacjeljivanja kod neke osobe, ili za sprječavanje ili smanjenje oštećenja mišića neke osobe, naznačena time da se laminin-1 daje sistemski i da se ta regeneracija mišića provodi nakon oštećenja, ozljede ili bolesti.
Pharmaceutical composition according to Claim 3, characterized in that it comprises a total amount of said cosolvents in the range from 30% to 85% (w/v). 
Farmaceutski sastav prema zahtjevu 3, naznačen time, da on sadrži ukupnu količinu spomenutih ko-otapala u rasponu od 30% do 85% (masa/volumen).
Cortexolone-17a-propionate in crystalline form III according to anyone of claims 15 to 18 for use in the treatment pathologies affecting the urogenital system, the endocrine system, the skin, and/or the cutaneous appendages. 
Korteksolon-17a-propionat u kristalnom obliku INI u skladu s bilo kojim od patentnih zahtjeva 15 do 18, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili derivate kože.
Method according to any one of claims 12-21, wherein the composition exhibits an absorption ratio A280/560 of at least 80, preferably of at least 250. 
Postupak prema bilo kojem od zahtjeva 12-21, naznačen time, što pripravak pokazuje apsorpcijski omjer A280/560 od najmanje 80, poželjno od najmanje 250.
Additional methods for the resolution of optical isomers, known to those skilled in the art, may be used. 
Dodatne metode, poznate osobama iz struke mogu se također upotrijebiti. Te metode uključuju i one o kojima diskutiraju J.
The formulation of claim 1, wherein the macrocyclic lactone is either ivermectin or eprinomectin and is present in an amount sufficient to deliver a dose of at least 150 µg/kg animal bodyweight. 
Formulacija prema zahtjevu 1, naznačena time, da makrociklički lakton je bilo ivermektin ili eprinomektin, i prisutan je u količini dovoljnoj za pripravu doze od najmanje 150 ug/kg prema masi životinje.
The compound or composition for use of claim 3, wherein the disease or disorder is skin cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je limfom.
The compound according to any one of the previous claims, wherein A1 and A2 are independently a direct bond or C1-6alkylene, wherein said C1-6alkylene is optionally substituted with one or more substituents selected from the group consisting of C1-6alkyl, C1-6alkenyl, C1-6alkynyl, halo, hydroxyl, oxo, amino, cyano, aryl, heteroaryl, cycloalkyl, alkylamino, alkoxy, alkylthio, acylamino, carbamate, urea, and sulfonamido 
Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time što A! i A? su neovisno izravna veza ili Crgalkilen, pri čemu je navedeni Cigalkilen izborno supstituiran s jednim ili više supstituenata odabranih iz skupine koja se sastoji od Cisalkila, C, galkenila, Ci.galkinila, halo, hidroksila, okso, amino, cijano, arila, heteroarila, cikloalkila, alkilamino, alkoksi, alkiltio, acilamino, karbamata, uree i sulfonamido.
initialisation of a system of encryption at first access by means of: 
inicijalizacije sustava enkripcije kod prvog pristupa putem:
The composition of claim 1 or claim 2, in which at least 98% by weight of the ApoA-I in the population is untruncated ApoA-I. 
Postupak prema zahtjevu 1 ili zahtjevu 2, naznačen time što se koraci (b) i (c) ponavljaju najmanje tri puta.
A synergistic herbicidal mixture comprising imazamox, its respective isomers a s well as its respective environmentally compatible salts or esters or amides or other derivatives; 
spoj izabran iz grupe koju čine sulfoniluree, uključujući njihove odgovarajuće izomere kao i njihove odgovarajuće soli ili estere ili amide ili druge derivate kompatibilne sa životnom sredinom;
a cost function that rewards the path of the fin with higher energy value; and 
- < funkcije troškova koja odabire put peraje s većom energetskom vrijednošću; i
A host cell transformed with the expression vector according to claim 10, which is selected from the group consisting of the following (a) to (d): 
Stanica domaćin, naznačena time što je se bira iz skupine koju čine sljedeće (a) do (d):
adding nicotine to the cooled homogeneous mass of step (c) and mixing to form a non-crystalline gel matrix; 
(c) kalupljenja smjese da bi se formirale tablete-pastile, pri čemu te tablete sadrže manje od 10 mas.% saharoze.
The pharmaceutical composition may be in the form of a capsule, granule, powder, solution, suspension, or tablet and is designed for administration by an oral, sublingual, buccal, parenteral, intravenous, transdermal, inhalation, intranasal, vaginal, intramuscular, or rectal mode. 
Farmaceutska kompozicija prema patentnom zahtjevu 3, naznačena time što je u obliku kapsule, granule, praška, otopine, suspenzije ili tablete 1 dizajnirana je za primjenu pomoću oralnog, subligvalnog, bukalnog, parenteralnog, intravenskog, transdermalnog, inhalacionog, intranazalnog, vaginalnog, intramuskularnog ili rektalnog načina.
Use of the carbostyril derivative or a salt thereof as set forth in claim 1 or 2, and donepezil or a salt thereof for the preparation of a medicament for treating Alzheimer's disease. 
Uporaba derivata karbostirila ili njegove soli kako je navedeno u zahtjevu 1 ili 2, te donepezila ili njegove soli naznačena time da je za pripravu lijeka za liječenje Alzheimerove bolesti.
The use of the protein Serum amyloid P-component (SAP, SAMP, SwissProt No: P02743), for prognosis and/or diagnosis of Trisomy 21 (Down syndrome) during pregnancy. 
Primjena proteinskog seruma amiloidne komponente P (SAP, SAMP, SwissProt br. PO2743) za prognozu i/ili dijagnozu trisomije 21 (Down-ovog sindroma) za vrijeme trudnoće.
Process of preparation of a conjugate according to any one of claims 14 to 16 comprising the step where a compound of formula (I) as defined in claim 1 in which T comprises a sulfide, disulfide or thiol group, or a precursor thereof, is reacted with a cell binding agent comprising a function reactive towards disulfide or thiol so that the compound and the cell binding agent are linked together via a sulfide or disulfide bond. 
Postupak dobivanja konjugata u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačen time što uključuje korak u kojem spoj u skladu s patentnim zahtjevom 1 koji sadrži sulfidnu, disulfidnu ili tiolnu skupinu, ili njegov preteča, reagira sa sredstvom za vezanje na stanicu, koje sadrži funkcionalnu skupinu reaktivnu prema disulfidu ili tiolu, tako da se spoj i sredstvo za vezanje na stanicu poveže zajedno preko sulfidne ili disulfidne veze.
Alternatively, the compound may have the formula: R1—Z—R2 
Spoj, naznačen time, da ima formulu:
disconnecting from a current network connection and reconnecting to the preferred network using the received subscriber network identifier. 
davanje uputa pretplatničkom mobilnom komunikacijskom uređaju (10, 20, 101) da se ponovno spoji s mrežom kojoj se daje prednost.
discharging solids from a heat exchanger through a plurality of solids flow control valves according to claim 1; discharging air into the shoe (126) to fluidize the solids; and 
Postupak naznačen time da sadrži: ispuštanje krutih tvari iz izmjenjivača topline kroz mnoštvo regulacijskih ventila za protok krute tvari prema zahtjevu 1;
A valve (100) according to claim 1, wherein said abutment member (300) has an annular shape comprising a through channel (310) adapted to allow passage of a gas flow from a container towards the second aperture (112). 
Ventil (100) u skladu s patentnim zahtjevom 1, naznačen time, da navedeni element za zaustavljanje (300) ima prstenasti oblik koji se sastoji od prolaznog kanala (310) prilagođen da omogući prolaz struje plina iz spremnika prema drugom otvoru (112).
Immunoglobulin single variable domains according to any of claims 1 to 5, that essentially consist of a VHH, a humanized VHH, or a camelized VH that has at least 80% amino acid identity with at least one of the amino acid sequences of SEQ ID NO's: 1 to 22, 237 to 247, and 2684 to 2717, in which for the purposes of determining the degree of amino acid identity, the amino acid residues that form the CDR sequences are disregarded; 
Trovalentni konstrukt prema bilo kojem od patentnih zahtjeva 1 ili 2, koji se u osnovi sastoji od tri imunoglobulinske jednostruke varijabilne domene koje se u osnovi sastoje od VHH, humaniziranog VHH, ili kamilidnog VH koje ima barem 80% identičnosti aminokiseline s barem jednom od sekvenci aminokiseline od SEQ ID NO: 1 do 22, 158 do 236, 248 do 407, 2448, i 2574 do 2581, u kojem se u svrhu određivanja stupnja identičnosti aminokiseline, zanemaruju aminokiselinski ostaci koji tvore CDR sekvence;
More preferably, the transformant of the present invention is either a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence encoding the heavy chain fragment of the above-described Fab' fragment of the present invention and a polynucleotide comprising a sequence encoding the light chain of the Fab' fragment, or a host cell transformed with an expression vector comprising a polynucleotide comprising a sequence encoding the heavy chain fragment of the above-mentioned Fab' of the present invention and an expression vector comprising a polynucleotide comprising a sequence encoding the light chain of the Fab' fragment. 
(a) stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira teškolančani fragment Fab* fragmenta u skladu s patentnim zahtjevom 1 i polinukleotid koji sadrži slijed koji kodira laki lanac Fab' fragmenta u skladu s patentnim zahtjevom 1; 1 (b) stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira teškolančani fragment Fab' fragmenta u skladu s patentnim zahtjevom 1 i ekspresijskim vektorom koji sadrži polinukleotid koji sadrži slijed koji kodira laki lanac Fab' fragmenta u skladu s patentnim zahtjevom 1,1 konjugiranju Fab* fragmenta protutijela protiv ljudskog NGF s polietilen-glikolom.
The solvent was evaporated off to obtain an oil which was purified on a Varian Mega Bond (flash master system) 70 g column (ethyl acetate, Rf=0.50), thereby obtaining a yellow solid. 
Otapalo je upareno i dobiveno je ulje koje je čišćeno na Varian Mega Veza (flash master system) koloni od 70 g (etil-acetat, Rf=0.50) i time je dobivena žuta krutina.
The method for determining clotting time in a fluid medium such as blood or plasma according to claim 11 further comprising a quality control step of correlating at least one property with a theoretical curve. 
. Postupak proizvodnje mikrofluidičkog uređaja u skladu s bilo kojim od patentnih zahtjeva 1-17 određivanja vremena koagulacije u fluiđdnom mediju, poput krvi ili plazme, naznačen time što se sastoji u sljedećim koracima:
to 112.5 g PEG having an average molecular weight of 2500 to 4500 Da, for example 100g; 
do 250 g po litri PEG koji ima prosječnu molekularnu težinu od 2500 do 4500 Da;
Process for the preparation of Sitagliptin of formula (I) or salt thereof: comprising of the following steps: 
Postupak priprave sitagliptina formule (I) ili njegove soli:
A method for diagnosing a predisposition to glaucoma, optic neuritis, or lattice dystrophy in a subject comprising detecting the specific binding of a monoclonal antibody comprising a light chain CDR1 having the amino acid sequence of SEQ ID NO: 9; a light chain CDR2 having the amino acid sequence of SEQ ID NO: 10; a light chain CDR3 having the amino acid sequence of SEQ ID NO: 11; a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 12; a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 13; and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 14, or a functional part thereof, to an epitope of the amyloid protein in a sample of the subject which includes the steps of 
Postupak dijagnosticiranja sklonosti ka glaukomu, optičkom neuritisu ili retikularnoj distrofiji kod subjekta koji se sastoji u detektiranju specifičnog vezanja monoklonskog protutijela koje sadrži CDRI lakog lanca s aminokiselinskim slijedom SEQ ID NO: 9; CDR2 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 10; CDR3 lakog lanca s aminokiselinskim slijedom SEQ ID NO: 11; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 12; CDRI teškog lanca s aminokiselinskim slijedom SEQ ID NO: 13; 1 CDR3 teškog lanca s aminokiselinskim slijedom SEQ ID NO: 14, ili njegovog funkcionalnog dijela, na epitop u amiloidnom proteinu u uzorku iz subjekta, naznačen time što uključuje korake:
The compound according to claim 9 wherein substructure IV is 
Spoj u skladu s patentnim zahtjevom 2, gdje podstruktura IV je [image]
The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, surfactants, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. 
Tekući nosač može sadržati i ostale prikladne farmaceutske aditive, kao što su sredstva za poboljšanje topljivosti, emulgatore, surfaktante, pufere, konzervanse, zaslađivače, sredstva za dodatak okusa, sredstva za suspenziju, sredstva za zadebljanje, boje, regulatore viskoznosti, stabilizatore ili osmo-granule.
The process according to any of claims 1 to 26, characterised in that the C8 to C24 aliphatic carboxylic acid(s) employed in step (b) are stearic and/or palmitic and/or myristic and/or lauric acids or mixtures thereof, and most preferably are stearic and/or palmitic acid. 
Uporaba proizvoda prema bilo kojem zahtjevu od 1 do 13 naznačena time da je za miješanje i/ili ekstrudiranje i/ili slaganje i/ili puhanje plastičnih materijala, te poželjno za poliolefine ili termoplastike kao što su polietilen (PE), polipropilen (PP), poliuretani (PU) i polivinilklorid (PVC).
The peptide according to claim 1 or 2, the nucleic acid or an expression vector according to claim 5, the cell according to claim 7, or the activated cytotoxic T lymphocyte according to claim 12 for use in the treatment of cancer, such as, for example, gastric, gastrointestinal, colorectal, pancreatic, lung or renal cancer. 
Peptid u skladu s patentnim zahtjevom 1 ili 2, nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5, stanica u skladu sa zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 12 za upotrebu u liječenju karcinoma, kao što su gastrični, gastrointestinalni, kolorektalni karcinomi te karcinomi gušterače, pluća ili bubrega.
hydrolysis of the product of step (b) to hydroxy methyl oxazolidinone compound of formula V 
Cc) hidroliziranje proizvoda iz koraka (b) za tvorbu hidroksimetil-oksazolidinona spoja formule V:
The method according to claim 23, characterised in that the base of Compound I is set free and precipitated in crystalline form, and then converted to a salt of Compound I. 
Postupak prema zahtjevu 23, naznačen time što se baza Spoja I oslobađa i taloži u kristaličnom obliku i zatim pretvara u sol Spoja I.
The recombinant protein of any one of claims 1 to 6, wherein the protein and/or the N-glycan(s) is(are) therapeutically and/or prophylactically active. 
Uporaba prema zahtjevu 1, gdje se protein modificira dodavanjem, brisanjem i/ili zamjenom jedne ili više aminokiselina u tom proteinu.